ClinicalTrials.gg
Not yet recruitingNCT07302308Updated Jan 21, 2026

Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders.

An observational study in Functional Movement Disorder, sponsored by Western University, Canada. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Western University, Canada · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

Functional movement disorders (FMD) are among the most common neurological conditions seen in clinical practice, yet they are poorly understood and often misdiagnosed. Impaired self-agency, the sense of controlling one's actions, is a key feature of FMD. Studies using functional MRI have shown reduced activation and connectivity in the right inferior parietal lobule, a region associated with agency.

The sense of agency consists of two components: the feeling of agency, which is an implicit, low-level sense of control over voluntary actions, and the judgment of agency, which is the conscious attribution of actions to oneself. While the feeling of agency is often measured using intentional binding tasks, judgment of agency is assessed using self-reported scales. While studies have explored intentional binding as a measure of implicit agency in FMD, few have systematically investigated judgment of agency. This study aims to fill this gap by introducing a novel approach that quantitatively evaluates judgment of agency in FMD patients using action-outcome latencies as an objective metric.

Read the detailed description

Objective: The objective of this study is to investigate the differences between patients with FMD and healthy controls in perceiving visual and auditory outcomes as consequences of their actions. This will be assessed by measuring their judgment of agency through action-outcome latencies.

02

Conditions studied

  • Functional Movement Disorder

Browse trials for

Keywords

  • functional movement disorder
  • sense of agency
  • judgment of agency
03

In context

Conversion Disorder

89 studies on the registry are indexed under Conversion Disorder; 34 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 37 observational studies indexed under Conversion Disorder.

Browse Conversion Disorder studies →

Lead sponsor

Western University, Canada is the lead sponsor of 224 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

movement disorder clinic

Eligibility criteria

Inclusion criteria for patients: Inclusion criteria for patients:

  1. Diagnosed with clinically definite functional movement disorder
  2. Age >18 years.
  3. Able to read and understand English.

Inclusion criteria for healthy subjects:

  1. Age >18 years.
  2. Able to read and understand English

Exclusion criteria for patients:

  1. Moderate to severe action tremor in the dominant hand limiting the ability to perform the task.
  2. Upper limb peripheral neuropathy.
  3. Unable to read and understand English.

Exclusion criteria for healthy subjects:

1. Unable to read and understand English.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cases

    Functional Movement Disorder

  • Controls

    Healthy subjects

06

What researchers measure

Primary outcomes

  1. SA Index

    Latencies values corresponding to positive ("YES") responses will be extracted. SA (Sense of Agency) Index will be computed by multiplying the 90th percentile latencies by the number of positive responses below this latency threshold and then dividing the result by the total number of responses (positive, negative and unsure) occurring below the same threshold.

    Time frame: Day 1

  2. Latencies

    The 90th percentile of latency values among trials with positive ("YES") responses.

    Time frame: Day 1

07

Study locations

1 site
  • University Hospital
    London, Ontario N6A5A5, Canada
08

References and documents

Individual participant data

Plan to share: No — At this time, IPD will not be shared due to confidentiality concerns.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07302308
Responsible party
Aditya Murgai (Assistant Professor, Western University, Canada) — Principal investigator
First posted
Dec 24, 2025
Start date
Jan 31, 2026 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Jan 21, 2026

Study contacts

Aditya Murgai, MBBS MD DM
Contact
aditya.murgai@lhsc.on.ca
15196633121

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion